Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (91-100 of 721) with videos related to

Pageof 73
Sort By:
European Urology|January 24, 2017
A PET for All Seasons: <sup>18</sup>F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?Wolfgang P Fendler, Matthias Eiber, Christian G Stief, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2025
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical TherapyFabio Turco, Silke Gillessen, Ken Herrmann, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|May 21, 2026
FDG PET Hybrid ImagingCaner Civan, Wolfgang P Fendler, Bernd J Krause, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2017
Therapy assessment in prostate cancer using choline and PSMA PET/CTFrancesco Ceci, Ken Herrmann, Boris Hadaschik, et al.
European Urology|October 20, 2024
Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate CancerWolfgang P Fendler, Viktor Grünwald, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2024
[<sup>177</sup>Lu]Lu-DOTATATE May Resensitize Neuroendocrine Tumors to Hormonal Therapy: Initial Clinical Experience in Renal CarcinoidAkram Al-Ibraheem, Ahmed Abdlkadir, Dhuha Al-Adhami, et al.
Nature Reviews. Clinical Oncology|September 9, 2025
The molecular blueprint of targeted radionuclide therapyIrina Primac, Kevin Tabury, Alpaslan Tasdogan, et al.
European Urology Open Science|August 31, 2022
Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients?Kelsey L Pomykala, Ken Herrmann, Louise Emmett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2009
18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancerBernd Joachim Krause, Ken Herrmann, Hinrich Wieder, et al.
Clinical Nuclear Medicine|October 25, 2013
Primary central nervous system lymphoma and meningioma in DOTATATE PET/CTConstantin Lapa, Mario Löhr, Christina Bluemel, et al.
Pageof 73

Showing results (91-100 of 721) with videos related to

Sort By:
Pageof 73
European Urology|January 24, 2017
A PET for All Seasons: <sup>18</sup>F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?Wolfgang P Fendler, Matthias Eiber, Christian G Stief, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2025
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical TherapyFabio Turco, Silke Gillessen, Ken Herrmann, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|May 21, 2026
FDG PET Hybrid ImagingCaner Civan, Wolfgang P Fendler, Bernd J Krause, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2017
Therapy assessment in prostate cancer using choline and PSMA PET/CTFrancesco Ceci, Ken Herrmann, Boris Hadaschik, et al.
European Urology|October 20, 2024
Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate CancerWolfgang P Fendler, Viktor Grünwald, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2024
[<sup>177</sup>Lu]Lu-DOTATATE May Resensitize Neuroendocrine Tumors to Hormonal Therapy: Initial Clinical Experience in Renal CarcinoidAkram Al-Ibraheem, Ahmed Abdlkadir, Dhuha Al-Adhami, et al.
Nature Reviews. Clinical Oncology|September 9, 2025
The molecular blueprint of targeted radionuclide therapyIrina Primac, Kevin Tabury, Alpaslan Tasdogan, et al.
European Urology Open Science|August 31, 2022
Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients?Kelsey L Pomykala, Ken Herrmann, Louise Emmett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2009
18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancerBernd Joachim Krause, Ken Herrmann, Hinrich Wieder, et al.
Clinical Nuclear Medicine|October 25, 2013
Primary central nervous system lymphoma and meningioma in DOTATATE PET/CTConstantin Lapa, Mario Löhr, Christina Bluemel, et al.
Pageof 73